Center for Optimization of Participant Engagement for Cancer Characterization (COPECC)
- Colorectal cancer
- University of Southern California
- Grant Number: U2C CA252971
Building a foundation for access to health care innovation for Hispanic/Latino cancer patients.
University of Southern California
CRC is the second leading cause of cancer mortality in the United States. Hispanic/Latino/a(x) (H/L) CRC patients tend to be diagnosed at a younger age and with higher stage, and it has also been reported that Mexican H/L in California have a higher proportion of young (<50 years of age) diagnoses compared to other H/L subgroups. Moreover, significant gaps persist in the availability of molecular profiling data from diverse cancer patient cohorts, including significant limitations in data from H/L cancer cases. A barrier to increasing diversity in biomedical research studies is the lack of culturally appropriate approaches to engaging and involving underrepresented minority communities for participation in research.
To address these challenges and to identify solutions to these issues, we have created the Center for Optimization of Participant Engagement for Cancer Characterization (COPECC) at the University of Southern California in Los Angeles. The overarching goal of COPECC is to build a foundation for access to health care innovation for Hispanic/Latino cancer patients. Our center will perform among the largest and most comprehensive studies to characterize the molecular features of CRC in H/L, particularly those with early onset cancer. These data will help the scientific community best understand the mechanisms driving CRC in our H/L population. Importantly, we will concurrently develop and optimize culturally tailored methods to best engage our H/L patient population towards developing optimized models that can be distributed broadly to advance increased representation in biomedical research studies.
- Engage H/L CRC patients using culturally tailored tools developed in collaboration with behavioral scientists, patient advocates, and Community Outreach and Engagement leaders.
- Comprehensively characterize the genomic tumor landscape and germline genetics of 500 H/L with CRC to address the knowledge gap for this patient population, with focus on early onset colorectal cancer.
- Continuously optimize our tools for patient engagement and for delivery of genomic and genetic information, and develop and test novel risk communication strategies for delivering information through rigorous approaches, incorporating patient preferences and needs.
John Carpten, PhD
Heinz-Josef Lenz, MD
Mariana Stern, PhD
David Craig, PhD
Lourdes Baezconde-Garbanati, PhD
Additional Team Members
Sandra Algaze, MD
Julie Culver, MS
James Gauderman, PhD
Natalia Gutierrez, MS
Daisy Hernandez, MS
Syma Iqbal, MD
Caryn Lerman, PhD
Juan Pablo Lewinger, PhD
Elizabeth Quino, MPH
Charite Ricker, MS
Janet Rodriguez, MPH
Joel Sanchez Mendez, MBBS MBA
Bodour Salhia, PhD
Jennifer Tsui, MD
Enrique Velazquez Villareal, MD